scispace - formally typeset
Open AccessJournal ArticleDOI

Treatment of Hyperthyroidism in Pregnancy and Birth Defects

TLDR
In this paper, the authors examined the association of both drugs with congenital malformations using data from the International Clearinghouse for Birth Defects Surveillance and Research (ICSBRS).
Abstract
Context: Clinical hyperthyroidism is not uncommon in pregnancy, with a reported prevalence of 0.1 to 0.4%. The available antithyroid drugs are propylthiouracil and methimazole/carbimazole. Objectives: In this report we examined the association of both drugs with congenital malformations using data from the International Clearinghouse for Birth Defects Surveillance and Research. Design: The study used a case-affected control analysis and included 18,131 cases with malformations and reported first-trimester exposure to medication. A total of 127 subjects were born to mothers with known first-trimester antithyroid drug exposure. Results: Among the 52 groups of malformations that were analyzed, situs inversus ± dextrocardia, isolated unilateral kidney a/dysgenesis, and cardiac outflow tract defects were associated with prenatal exposure to propylthiouracil based on three, two, and five cases, respectively. Prenatal exposure to methimazole/carbimazole was significantly associated with choanal atresia, omphaloc...

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation

TL;DR: In utero exposure to MMI during the first trimester of pregnancy increased the rate of congenital malformations, and it significantly increased the rates of aplasia cutis congenita, omphalocele, and a symptomatic omphalomesenteric duct anomaly.
Journal ArticleDOI

Diagnosis and management of Graves disease: a global overview

TL;DR: Measurements of serum levels of TRAb and thyroid ultrasonography represent the most important diagnostic tests for Graves disease, and novel agents that might act on the disease process are currently under evaluation in preclinical or clinical studies, but evidence of their efficacy and safety is lacking.
Journal ArticleDOI

Birth Defects After Early Pregnancy Use of Antithyroid Drugs: A Danish Nationwide Study

TL;DR: In this paper, a Danish nationwide register-based cohort study included 817 093 children live-born from 1996 to 2008, and exposure groups were assigned according to maternal antithyroid drug use in early pregnancy: PTU (n = 564), methimazole (MMI)/CMZ), MMI/CMZ and propylthiouracil (PTU).
References
More filters
Journal ArticleDOI

Clinical practice guideline: Management of thyroid dysfunction during pregnancy and postpartum: An endocrine society clinical practice guideline

TL;DR: Management of thyroid diseases during pregnancy requires special considerations because pregnancy induces major changes in thyroid function, and maternal thyroid disease can have adverse effects on the pregnancy and the fetus.
Journal ArticleDOI

Fetal and neonatal hyperthyroidism.

TL;DR: Hyperthyroid neonates may be treated with antithyroid drugs, beta-adrenergic receptor blocking agents, iodine, or iodinated contrast agents, and at times, with glucocorticoids and digoxin, and the time course of thyrotoxicosis depends on etiology.
Journal ArticleDOI

Hyperthyroidism in pregnancy.

TL;DR: The syndrome of transient hyperthyroidism of hyperemesis gravidarum is defined as severe nausea and vomiting, dehydration, ketonuria, and weight loss of more than 5% by 6 to 9 weeks of pregnancy.
Journal ArticleDOI

Methimazole embryopathy: delineation of the phenotype.

TL;DR: A specific malformation pattern related to prenatal methimazole exposure and consisting of choanal and esophageal atresia, scalp defects, minor facial anomalies and psychomotor delay is defined.
Related Papers (5)